Study of Moxibustion to Prevent Hemorrhagic Cystitis After Allogeneic Stem Cell Transplantation in Patients Aged 14 to 60

What this Trial Is About

Researchers are evaluating the use of moxibustion to prevent hemorrhagic cystitis HC in patients undergoing allogeneic hematopoietic stem cell transplantation allo-HSCT for blood diseases. This multicenter, randomized controlled study plans to enroll 266 patients aged 14 to 60 years with pernicious blood diseases or severe aplastic anemia receiving allo-HSCT. The goal is to assess whether moxibustion can reduce the incidence and severity of HC after transplantation. Participants are randomly divided into two groups. The experimental group receives moxibustion treatment applied to specific points Zhongji, Guanyuan, and Qihai for 30 minutes daily starting the first day after HSCT until day 14 post-transplant. The control group receives conventional symptomatic treatment. Urine tests for routine analysis and viruses are collected at admission, day 1, day 14, symptom onset, and remission of HC. Routine urine tests continue every 7 days for 100 days. During the study, researchers monitor HC symptoms daily in affected patients, including pain and severity scores, medication use, and traditional Chinese medicine evidence. Outcomes include highest pain score within 100 days post-transplant, incidence of HC, blood cell implantation rates, graft-versus-host disease, viral reactivation, infections, and mortality. Participants are followed for 100 days to evaluate these outcomes and treatment effects.

Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT